公开(公告)号：US10006920B2

公开(公告)日：2018-06-26

申请号：US14787146

申请日：2014-04-25

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Young Soo Kim ,  Dong Jin Kim ,  Hye Yun Kim ,  Soo Min Cho ,  Tae Song Kim ,  Hyunjin Kim ,  Sejin Lee ,  Kyoseon Hwang ,  Jee Hoon Roh ,  Jae-Young Koh

IPC: G01N33/68 ,  A61K38/17 ,  C07K14/47

CPC classification number: G01N33/6893 ,  A61K38/1716 ,  C07K14/4711 ,  G01N33/6827 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

Abstract: The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of β-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

公开(公告)号：US09527824B2

公开(公告)日：2016-12-27

申请号：US14316963

申请日：2014-06-27

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dong Jin Kim ,  Young Soo Kim ,  Hye Yun Kim ,  Hyun Jin Kim

IPC: A61K31/535 ,  C07D295/15 ,  A61K31/495 ,  A61K31/5375 ,  C07D295/088

CPC classification number: C07D295/15 ,  A61K31/495 ,  A61K31/5375 ,  C07D295/088

Abstract: Provided is a pharmaceutical composition for preventing or treating a cognitive impairment-related disease, the pharmaceutical composition including N-(2-hydroxyethyl)piperazine-N′(3-propane sulfonic acid), a pharmaceutically acceptable salt thereof or a derivative thereof, and donepezil, a pharmaceutically acceptable salt thereof or a derivative thereof. The composition may be used in preventing or treating a cognitive impairment-related disease.

Abstract translation: 提供了用于预防或治疗认知障碍相关疾病的药物组合物，所述药物组合物包括N-（2-羟乙基）哌嗪-N'（3-丙磺酸），其药学上可接受的盐或其衍生物，以及 多奈哌齐，其药学上可接受的盐或其衍生物。 该组合物可用于预防或治疗认知障碍相关疾病。

公开(公告)号：US10544427B2

公开(公告)日：2020-01-28

申请号：US15709822

申请日：2017-09-20

Applicant: Korea Institute of Science and Technology

Inventor： Do Hee Kim ,  Seul Gi Shin ,  Sung Su Lim ,  Ae Nim Pae ,  Dong Jin Kim ,  Yun Kyung Kim

IPC: A01K67/027 ,  C12N15/85 ,  C07K14/47 ,  G01N33/50 ,  G01N33/68

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

公开(公告)号：US20180119169A1

公开(公告)日：2018-05-03

申请号：US15709822

申请日：2017-09-20

Applicant: Korea Institute of Science and Technology

Inventor： Do Hee KIM ,  Seul Gi Shin ,  Sung Su Lim ,  Ae Nim Pae ,  Dong Jin Kim ,  Yun Kyung Kim

IPC: C12N15/85 ,  A01K67/027 ,  G01N33/50 ,  C07K14/47 ,  G01N33/68

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C07K14/47 ,  C07K2319/60 ,  C12N2015/8527 ,  C12N2015/8536 ,  C12N2015/859 ,  C12N2830/008 ,  G01N33/5058 ,  G01N33/5088 ,  G01N33/6896 ,  G01N2800/2814

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

公开(公告)号：US20150065494A1

公开(公告)日：2015-03-05

申请号：US14389609

申请日：2013-04-01

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dong Jin Kim ,  Kyung Ho Yoo ,  Young Soo Kim ,  Woong Seo Park ,  Yong Koo Kang ,  Hye Yun Kim ,  Yun Kyung Kim ,  Ki Duk Park ,  Maeng Sup Kim ,  Kwee Hyun Suh ,  Young Gil Ahn

IPC: C07D413/12 ,  C07D405/12 ,  C07D307/81

CPC classification number: C07D413/12 ,  C07D307/81 ,  C07D405/12

Abstract: The present invention provides an aminostyrylbenzofuran compound of Formula (I), and a pharmaceutical composition comprising same. The pharmaceutical composition of the present invention comprising the compound of Formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof as an active ingredient can be useful for the prevention and treatment of degenerative brain diseases caused by accumulation of beta-amyloid.

Abstract translation: 本发明提供式（I）的氨基苯乙烯基苯并呋喃化合物和包含其的药物组合物。 包含式（I）化合物，其药学上可接受的盐，异构体，水合物和溶剂合物作为活性成分的本发明的药物组合物可用于预防和治疗由积累引起的退行性脑病 的β-淀粉样蛋白。